208459-84-1

Upstream product

• 123148-78-7 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 98-09-9 benzenesulfonyl chloride 
• 3680-71-5 1H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1939-99-7 benzenesulfonyl chloride 
• 123148-78-7 4-chloro-5-iodopyrrolo[2,3-d]-pyrimidine 

Downstream Products

• 344891-59-4 7-Benzenesulfonyl-4-chloro-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidine 
• 208459-82-9 (3-bromo-phenyl)-[5-(4-chloro-phenyl)-7H-pyrrolo[2,3-d]pyrimidin4-yl]-amine 
• 54060-30-9 3-acetylenephenylamine 
• 1111235-36-9 C₂₀H₁₇IN₄O₄S 
• 1111235-21-2 C₂₃H₂₁IN₄O₆S 
• 1111236-56-6 C₂₁H₁₉IN₄O₅S 
• 1344667-03-3 tert-butyl N-[5-[[7-(benzenesulfonyl)-4-methylamino-pyrrolo[2,3-d]pyrimidin-5-yl]-hydroxy-methyl]-6-fluoro-2-pyridyl]-N-(6-methyl-3-pyridyl)carbamate 
• 1344667-04-4 tert-butyl N-[5-[7-(benzenesulfonyl)-4-methylamino-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-6-fluoro-2-pyridyl]-N-(6-methyl-3-pyridyl)carbamate 
• 1289183-63-6 (S)-2-(((5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)thiophen-2-yl)methyl)amino)-N-(1-(4-fluorophenyl)ethyl)nicotinamide 
• 1289179-49-2 2-[4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzylamino]-5-cyano-N-[(S)-1-(4-fluorophenyl)ethyl]nicotinamide 
• 208459-78-3 4-chloro-5-(4-methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

PYRROLOPYRIMIDINE ITK INHIBITORS

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

NEW BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I); wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicaments.

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereo

AXL KINASE INHIBITORS

Axl kinase inhibitory compounds are disclosed, as well as compositions and methods of using the same in the treatment of cancer and other conditions mediated by and/or associated with Axl kinase.

Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use

Novel pyrrolo[2,3-d]pyrimidine compounds useful as inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 as well as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases are described.

Pyrrolo[2,3-d]pyrimidine compounds

A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.